A Sheffield-based start up, Retrogenix, which has developed a specialist cell microarray technology to screen drugs against human proteins, secured £150,000 of equity funding from Yorkshire Forward’s Access to Finance for Healthcare Technology Companies programme.
Founded in October 2008, Retrogenix is the first company to secure funding through the the Access to Finance programme following its launch in February. This gives healthcare technology companies in Yorkshire the tools and resources needed to access equity funding from national and international investors.
Retrogenix has attracted three business angels: Neil Ewin and Mark Woodward of Ewin Woodward Development and Nick Stringer, who will be involved at board level.
The funds will be used to scale-up its services for pharmaceutical companies.